CL2014000210A1 - Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion. - Google Patents

Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.

Info

Publication number: CL2014000210A1
Authority: CL; Chile
Prior art keywords: depression; disease; useful; treatment; condition
Prior art date: 2011-07-28

Application number

CL2014000210A

Other languages

English (en)

Inventor

Sven Guenther

Guochen Chi

Bindu Bera

Travis Mickle

Original Assignee

Kempharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-28

Filing date

2014-01-28

Publication date

2014-09-26

2014-01-28 Application filed by Kempharm Inc filed Critical Kempharm Inc

2014-09-26 Publication of CL2014000210A1 publication Critical patent/CL2014000210A1/es

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 title 1
230000006735 deficit Effects 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000013403 hyperactivity Diseases 0.000 title 1
229960001344 methylphenidate Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
210000000653 nervous system Anatomy 0.000 title 1
229940002612 prodrug Drugs 0.000 title 1
239000000651 prodrug Substances 0.000 title 1
230000000638 stimulation Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Psychiatry (AREA)
Crystallography & Structural Chemistry (AREA)
Nutrition Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Physiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)

CL2014000210A 2011-07-28 2014-01-28 Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion. CL2014000210A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161512658P	2011-07-28	2011-07-28

Publications (1)

Publication Number	Publication Date
CL2014000210A1 true CL2014000210A1 (es)	2014-09-26

Family

ID=47601775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000210A CL2014000210A1 (es)	2011-07-28	2014-01-28	Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.

Country Status (29)

Country	Link
US (4)	US9079928B2 (es)
EP (2)	EP2736510B1 (es)
JP (4)	JP5976111B2 (es)
KR (5)	KR20190085184A (es)
CN (2)	CN107261148B (es)
AR (1)	AR087390A1 (es)
AU (1)	AU2012286683C1 (es)
BR (1)	BR112014002084B1 (es)
CA (3)	CA3123900A1 (es)
CL (1)	CL2014000210A1 (es)
CO (1)	CO6900135A2 (es)
DK (1)	DK2736510T3 (es)
ES (2)	ES2883259T3 (es)
HR (1)	HRP20170555T1 (es)
HU (1)	HUE032113T2 (es)
IL (5)	IL230650A (es)
LT (1)	LT2736510T (es)
MX (3)	MX362571B (es)
MY (1)	MY162499A (es)
PH (1)	PH12014500049A1 (es)
PL (1)	PL2736510T3 (es)
PT (1)	PT2736510T (es)
RS (1)	RS55812B1 (es)
RU (1)	RU2573835C2 (es)
SG (1)	SG10201606225XA (es)
SI (1)	SI2736510T1 (es)
UA (1)	UA112654C2 (es)
WO (1)	WO2013016668A2 (es)
ZA (1)	ZA201308766B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2883259T3 (es) *	2011-07-28	2021-12-07	Kempharm Inc	Profármacos de metilfenidato, procesos para la obtención y uso de los mismos
NZ722096A (en)	2011-12-15	2016-11-25	Alkermes Pharma Ireland Ltd	Prodrugs of secondary amine compounds
EP2903614B1 (en) *	2012-10-05	2021-09-29	Sphaera Pharma Pte. Ltd	Novel compounds, their synthesis and their uses
WO2015001499A2 (en) *	2013-07-04	2015-01-08	Mahesh Kandula	Compositions and methods for the treatment of irritable bowel syndrome and the associated abdominal cramping
CN104418797B (zh) *	2013-08-26	2019-04-19	上海医药集团股份有限公司	哌甲酯、右哌甲酯的制备方法、其中间体及制备方法
US20170056352A1 (en)	2015-08-25	2017-03-02	Rgenix, Inc.	PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
US10662146B2 (en)	2015-09-15	2020-05-26	Praxis Bioresearch, LLC	Prodrugs of fencamfamine
AU2017348305B2 (en)	2016-10-31	2022-04-21	Biocryst Pharmaceuticals, Inc.	Prodrugs of kallikrein inhibitors
CA3046486A1 (en) *	2016-12-11	2018-06-14	Kempharm, Inc.	Compositions comprising methylphenidate-prodrugs, processes of making and using the same
WO2018107131A1 (en) *	2016-12-11	2018-06-14	Kempharm, Inc.	Methylphenidate-prodrugs, processes of making and using the same
WO2018160178A1 (en)	2017-03-01	2018-09-07	Rgenix, Inc.	Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
WO2018191219A1 (en) *	2017-04-11	2018-10-18	Thottathil John K	Novel alpha-hydroxy carboxylic acid and derivatives and other gras- based amide and imide prodrugs of amphetamine compounds and uses thereof
WO2019216664A1 (ko)	2018-05-10	2019-11-14	주식회사 헬릭스미스	주의력결핍과잉행동장애 치료용 생약조성물
US20220040318A1 (en) *	2018-09-28	2022-02-10	Seikagaku Corporation	Primary amine compound or secondary amine compound-acidic polysaccharide conjugate and production method therefor
US11174229B2 (en) *	2018-10-29	2021-11-16	Kempharm, Inc.	D-amphetamine compounds, compositions, and processes for making and using the same
EP3991730A4 (en) *	2019-06-28	2023-08-09	Shanghai Shengdi Pharmaceutical Co., Ltd	NEUROKININ-1 ANTAGONIST
JP2023505687A (ja)	2019-12-11	2023-02-10	インスピルナ，インコーポレーテッド	癌の処置方法
WO2021173533A1 (en) *	2020-02-29	2021-09-02	Kempharm, Inc.	Compositions comprising methylphenidate-prodrugs, processes of making and using the same
JP2024502909A (ja) *	2020-12-24	2024-01-23	アルマルソン、オーン	キサントフィル誘導体
IL316768A (en)	2022-05-25	2025-01-01	Ikena Oncology Inc	MEK inhibitors and their uses
WO2026019768A1 (en) *	2024-07-16	2026-01-22	Curia Global, Inc.	Aminomethyl carbamate compounds and derivatives and methods of their making

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4428935A (en) *	1982-05-24	1984-01-31	Pfizer Inc.	Penicillanic acid dioxide prodrug
US6210705B1 (en) *	1997-12-15	2001-04-03	Noven Pharmaceuticals, Nc.	Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
WO1999036403A1 (en) *	1998-01-13	1999-07-22	The Trustees Of The University Of Pennsylvania	Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same
US7060708B2 (en)	1999-03-10	2006-06-13	New River Pharmaceuticals Inc.	Active agent delivery systems and methods for protecting and administering active agents
IL150929A0 (en) *	2000-01-28	2003-06-24	Rohm & Haas	Pharmaceutical compounds comprising a pharmaceutically active moiety and a moiety comprising a substituent that enhances its properties
US20020132793A1 (en) *	2000-08-28	2002-09-19	Mel Epstein	Use of methylphenidate compounds to enhance memory
WO2002017919A2 (en) *	2000-08-28	2002-03-07	Sention, Inc.	Use of threo-methylphenidate compounds to enhance memory
US7700561B2 (en)	2002-02-22	2010-04-20	Shire Llc	Abuse-resistant amphetamine prodrugs
US7247730B2 (en)	2003-03-07	2007-07-24	Isp Investments Inc.	Process for the preparation of dexmethylphenidate hydrochloride
FI120187B (fi) *	2003-03-14	2009-07-31	Outotec Oyj	Menetelmä prosessin säätämiseksi
EP1812390A2 (en) *	2004-10-22	2007-08-01	Mark Froimowitz	Methylphenidate analogs and methods of use thereof
EP1928881A2 (en)	2005-08-19	2008-06-11	Pharmacofore, Inc.	Prodrugs of active agents
CN101678120A (zh) *	2006-12-05	2010-03-24	纽罗吉斯克斯公司	前药及其制备和使用方法
ES2364865T3 (es) *	2006-12-11	2011-09-15	Kempharm, Inc.	Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
CN101631770A (zh) *	2007-02-02	2010-01-20	科露西德医药品公司	抑制胆碱酯酶的化合物
AU2008214380A1 (en) *	2007-02-02	2008-08-14	Colucid Pharmaceuticals, Inc.	Compounds that inhibit cholinesterase
EP2433655A3 (en) *	2007-02-08	2013-05-15	Kempharm, Inc.	Homoarginine-prodrugs of amphetamine
CA2679741A1 (en) *	2007-03-15	2008-09-18	Sun Pharma Advanced Research Company Ltd.	Novel prodrugs
JP4881476B2 (ja) *	2007-05-23	2012-02-22	メルク・シャープ・エンド・ドーム・コーポレイション	ピリジルピペリジン・オレキシン受容体アンタゴニスト
JP2010533717A (ja) *	2007-07-18	2010-10-28	コルシド・ファーマシューティカルズ・インコーポレイテッド	覚醒を促進する方法
US8318813B2 (en)	2007-09-13	2012-11-27	Lcs Group, Llc	Method of treating binge eating disorder
ES2883259T3 (es)	2011-07-28	2021-12-07	Kempharm Inc	Profármacos de metilfenidato, procesos para la obtención y uso de los mismos
NZ722096A (en)	2011-12-15	2016-11-25	Alkermes Pharma Ireland Ltd	Prodrugs of secondary amine compounds

2012
- 2012-07-27 ES ES17157635T patent/ES2883259T3/es active Active
- 2012-07-27 BR BR112014002084-1A patent/BR112014002084B1/pt active IP Right Grant
- 2012-07-27 WO PCT/US2012/048641 patent/WO2013016668A2/en not_active Ceased
- 2012-07-27 RU RU2014107678/04A patent/RU2573835C2/ru active
- 2012-07-27 RS RS20170338A patent/RS55812B1/sr unknown
- 2012-07-27 HR HRP20170555TT patent/HRP20170555T1/hr unknown
- 2012-07-27 MX MX2016010664A patent/MX362571B/es unknown
- 2012-07-27 AU AU2012286683A patent/AU2012286683C1/en active Active
- 2012-07-27 KR KR1020197020055A patent/KR20190085184A/ko not_active Ceased
- 2012-07-27 LT LTEP12817423.2T patent/LT2736510T/lt unknown
- 2012-07-27 KR KR1020197020054A patent/KR20190085183A/ko not_active Ceased
- 2012-07-27 UA UAA201402019A patent/UA112654C2/uk unknown
- 2012-07-27 KR KR1020137034565A patent/KR101616111B1/ko active Active
- 2012-07-27 JP JP2014523083A patent/JP5976111B2/ja active Active
- 2012-07-27 MX MX2019001093A patent/MX375715B/es active IP Right Grant
- 2012-07-27 MY MYPI2013004688A patent/MY162499A/en unknown
- 2012-07-27 CN CN201710268246.0A patent/CN107261148B/zh active Active
- 2012-07-27 US US14/234,440 patent/US9079928B2/en active Active
- 2012-07-27 KR KR1020187017033A patent/KR20180069934A/ko not_active Ceased
- 2012-07-27 PT PT128174232T patent/PT2736510T/pt unknown
- 2012-07-27 CA CA3123900A patent/CA3123900A1/en active Pending
- 2012-07-27 ES ES12817423.2T patent/ES2621306T3/es active Active
- 2012-07-27 DK DK12817423.2T patent/DK2736510T3/en active
- 2012-07-27 EP EP12817423.2A patent/EP2736510B1/en active Active
- 2012-07-27 EP EP17157635.8A patent/EP3189840B1/en active Active
- 2012-07-27 SG SG10201606225XA patent/SG10201606225XA/en unknown
- 2012-07-27 CA CA2837732A patent/CA2837732C/en active Active
- 2012-07-27 PL PL12817423T patent/PL2736510T3/pl unknown
- 2012-07-27 KR KR1020167010571A patent/KR101869885B1/ko active Active
- 2012-07-27 CA CA2984544A patent/CA2984544C/en active Active
- 2012-07-27 PH PH1/2014/500049A patent/PH12014500049A1/en unknown
- 2012-07-27 CN CN201280037735.0A patent/CN103826633B/zh active Active
- 2012-07-27 HU HUE12817423A patent/HUE032113T2/en unknown
- 2012-07-27 SI SI201230904A patent/SI2736510T1/sl unknown
- 2012-07-27 MX MX2013015088A patent/MX341416B/es active IP Right Grant
- 2012-07-30 AR ARP120102779A patent/AR087390A1/es active IP Right Grant
2013
- 2013-11-21 ZA ZA2013/08766A patent/ZA201308766B/en unknown
- 2013-12-02 CO CO13282303A patent/CO6900135A2/es not_active Application Discontinuation
2014
- 2014-01-26 IL IL230650A patent/IL230650A/en active IP Right Grant
- 2014-01-28 CL CL2014000210A patent/CL2014000210A1/es unknown
2015
- 2015-06-01 US US14/727,498 patent/US9453037B2/en active Active
2016
- 2016-06-28 IL IL246503A patent/IL246503A/en active IP Right Grant
- 2016-07-15 JP JP2016139995A patent/JP6272403B2/ja active Active
- 2016-08-26 US US15/249,088 patent/US10231960B2/en active Active
2017
- 2017-08-24 IL IL254143A patent/IL254143B/en active IP Right Grant
- 2017-12-28 JP JP2017253020A patent/JP6505822B2/ja active Active
2018
- 2018-10-21 IL IL26249318A patent/IL262493B/en active IP Right Grant
2019
- 2019-01-10 US US16/244,460 patent/US20190142815A1/en not_active Abandoned
- 2019-03-26 JP JP2019058283A patent/JP6731090B2/ja active Active
- 2019-09-12 IL IL269322A patent/IL269322B/en active IP Right Grant

Also Published As

Publication number	Publication date
MX375715B (es)	2025-03-06
MX362571B (es)	2019-01-25
AR087390A1 (es)	2014-03-19
BR112014002084B1 (pt)	2022-03-29
JP5976111B2 (ja)	2016-08-23
SI2736510T1 (sl)	2017-05-31
CA2837732C (en)	2018-03-20
LT2736510T (lt)	2017-04-25
KR101616111B1 (ko)	2016-04-27
MX341416B (es)	2016-08-19
US9079928B2 (en)	2015-07-14
EP2736510A4 (en)	2015-02-25
US20170049765A1 (en)	2017-02-23
IL262493B (en)	2019-10-31
KR20140081761A (ko)	2014-07-01
JP6731090B2 (ja)	2020-07-29
KR20190085184A (ko)	2019-07-17
IL254143A0 (en)	2017-10-31
HUE032113T2 (en)	2017-09-28
US10231960B2 (en)	2019-03-19
CN107261148B (zh)	2021-07-13
CO6900135A2 (es)	2014-03-20
HRP20170555T1 (hr)	2017-06-16
IL269322A (en)	2019-11-28
IL254143B (en)	2018-11-29
KR101869885B1 (ko)	2018-06-25
JP6272403B2 (ja)	2018-01-31
AU2012286683C1 (en)	2016-04-21
KR20190085183A (ko)	2019-07-17
EP2736510A2 (en)	2014-06-04
EP2736510B1 (en)	2017-03-01
CA2984544A1 (en)	2013-01-31
IL230650A0 (en)	2014-03-31
RS55812B1 (sr)	2017-08-31
PH12014500049A1 (en)	2016-07-29
MX2019001093A (es)	2019-07-04
US9453037B2 (en)	2016-09-27
IL269322B (en)	2020-05-31
JP2019112462A (ja)	2019-07-11
JP2016222692A (ja)	2016-12-28
IL262493A (en)	2018-12-31
US20140243291A1 (en)	2014-08-28
CA3123900A1 (en)	2013-01-31
AU2012286683B2 (en)	2015-12-17
PL2736510T3 (pl)	2017-07-31
EP3189840A1 (en)	2017-07-12
CA2837732A1 (en)	2013-01-31
US20190142815A1 (en)	2019-05-16
IL246503A (en)	2017-09-28
CA2984544C (en)	2021-08-31
RU2014107678A (ru)	2015-09-10
KR20180069934A (ko)	2018-06-25
IL230650A (en)	2016-12-29
ES2883259T3 (es)	2021-12-07
MY162499A (en)	2017-06-15
DK2736510T3 (en)	2017-04-24
MX2013015088A (es)	2014-02-11
UA112654C2 (uk)	2016-10-10
US20150266911A1 (en)	2015-09-24
ZA201308766B (en)	2015-02-25
NZ618113A (en)	2015-06-26
CN107261148A (zh)	2017-10-20
EP3189840B1 (en)	2021-05-19
SG10201606225XA (en)	2016-09-29
KR20160047599A (ko)	2016-05-02
JP6505822B2 (ja)	2019-04-24
JP2014521656A (ja)	2014-08-28
RU2573835C2 (ru)	2016-01-27
WO2013016668A3 (en)	2013-03-21
WO2013016668A2 (en)	2013-01-31
CN103826633B (zh)	2017-05-24
BR112014002084A2 (pt)	2017-06-13
ES2621306T3 (es)	2017-07-03
CN103826633A (zh)	2014-05-28
PT2736510T (pt)	2017-04-05
JP2018076359A (ja)	2018-05-17

Publication	Publication Date	Title
CL2014000210A1 (es)	2014-09-26	Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112015006019A2 (pt)	2017-07-04	composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção.
GT201400164A (es)	2015-06-02	Compuestos de imidazopirrolidinona
AR090465A1 (es)	2014-11-12	Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MX2018013333A (es)	2020-11-12	Composiciones de nucleasas terapeuticas y metodos.
CL2014002334A1 (es)	2015-04-17	Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
HN2012000023A (es)	2014-08-18	Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2014011134A (es)	2014-12-10	Compuestos de carbamato y preparacion y uso de los mismos.
PE20150631A1 (es)	2015-05-11	Formas cristalinas de un modulador del receptor androgenico
AR125920A2 (es)	2023-08-23	Composiciones que comprenden vortioxetina y donepezil
PE20141906A1 (es)	2014-12-05	Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
CR20120202A (es)	2012-06-12	Métodos y composiciones para tratar cáncer
BR112015001098A2 (pt)	2017-08-08	composto, composição farmacêutica e método para o tratamento de uma condição de doença.
ECSP16078782A (es)	2017-02-24	Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
PT2729151T (pt)	2021-05-25	Composição farmacêutica, métodos de tratamento e suas utilizações
EA201270720A1 (ru)	2013-03-29	Модуляторы рецептора андрогенов и их применение
CL2011000043A1 (es)	2011-10-28	Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
MX382516B (es)	2025-03-13	Composiciones y metodos para absorcion transmucosa.
CL2014003429A1 (es)	2015-03-27	Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
CO7071139A2 (es)	2014-09-30	Tratamiento contra el cáncer cerebral
UY32937A (es)	2011-05-31	Compuestos y composiciones como moduladores de la actividad de gpr119
BR112013031712A2 (pt)	2017-07-04	composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
CL2015001610A1 (es)	2015-08-07	Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
CL2008002809A1 (es)	2009-11-27	Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros.